ABILIFY MAINTENA and ASIMTUFII injection administration in NYC and Long Island

Maintena and Asimtufii are distinct products

Maintena is a monthly aripiprazole injection into the shoulder or buttock muscle. Asimtufii is a separate two-month formulation given into the buttock muscle only. Both have adult schizophrenia and bipolar I maintenance monotherapy indications, but they have their own strengths, start regimens, interaction adjustments and late-dose rules. Discuss previous response, side effects, preference and appointment needs with the prescriber. A longer interval is not an automatic improvement or a dose-equivalent substitution. Ask for the exact product and written transition plan before changing visits.

Abilify Maintena

Abilify Maintena is a long-acting aripiprazole injection for adults with schizophrenia and for maintenance treatment of bipolar I disorder on its own. A healthcare professional gives it into the shoulder or buttock muscle, usually once a month. The label says not to give a maintenance dose sooner than 26 days after the previous injection. Its role is ongoing treatment. It is not the same product as oral Abilify, Abilify Asimtufii, Aristada or Aristada Initio.

How Abilify Maintena works

Aripiprazole acts at dopamine and serotonin receptors. Its effect is thought to involve partial activation of some receptors and blocking others. The exact way it produces clinical benefit is not fully known. The injection releases medicine over time, which changes the daily-pill routine but does not remove the need to review symptoms or side effects.

Eligibility: Abilify Maintena

The clinician reviews the diagnosis, previous benefit, side effects and whether aripiprazole is tolerated by mouth. For someone who has never taken it, oral tolerability must be established first. A medication review also checks drugs that change aripiprazole levels, including certain antidepressants, antibiotics and seizure medicines. The long-lasting formulation makes this review important before committing to an injection.

What to expect: Abilify Maintena

Review the treatment goal

Discuss what you want to improve and what makes daily tablets difficult. Include sleep, voices, mood stability, work and side effects. An injection is one treatment choice, not a judgement about how well you follow instructions.

Choose and document initiation

One labelled option uses two separate Maintena injections and one oral aripiprazole dose in a day. Another uses one injection with 14 consecutive days of oral aripiprazole or the current oral antipsychotic. The prescriber selects the appropriate regimen and checks interactions.

Keep maintenance and psychiatric review connected

Each administration record should show the exact dose, date and next due date. Psychiatric follow-up reviews whether the treatment still meets your goals. A community injection visit does not replace that review.

Risks and when to seek help

The boxed warning states that antipsychotics increase the risk of death in older adults with dementia-related psychosis. This medicine is not approved for that use. Weight gain, restlessness, injection-site pain and sedation are common effects in the schizophrenia studies. Monitoring includes weight, blood sugar, cholesterol, blood pressure and movement symptoms. Report new urges to gamble, shop, eat compulsively or engage in sexual activity. Aripiprazole can impair thinking or movement. Avoid driving until you know how it affects you. Seek emergency care for severe trouble breathing, throat or tongue swelling, loss of consciousness, or high fever with severe muscle stiffness and confusion. Contact the treating team promptly for new involuntary movements, severe restlessness, worsening psychosis, marked dizziness or troublesome injection-site symptoms. Do not wait for the next routine injection to report a serious concern.

Follow-up and treatment review

If the second or third dose is late, the restart threshold differs from the fourth or later doses. More than five weeks after an early dose or more than six weeks after later maintenance can require a new initiation regimen. Give the team your actual injection dates. Do not decide that you can safely skip treatment because you still feel well.

A two-month option versus monthly treatment

Asimtufii has its own two-month formulation and gluteal administration instructions. Maintena is a different monthly product with shoulder or buttock administration. The labels share adult schizophrenia and bipolar I maintenance monotherapy indications, but their regimens are not interchangeable. A planned switch from established Maintena follows specified timing and a prescriber review of the previous strength, response and interactions. Ask which appointment the new medicine replaces and how interim follow-up continues. Do not combine or stretch old injections to create a two-month schedule.

Abilify Asimtufii

Abilify Asimtufii is a long-acting aripiprazole injection given into the buttock muscle every two months. It is approved for adults with schizophrenia and for maintenance treatment of bipolar I disorder on its own. It can reduce how often you need an injection, but it does not reduce the importance of psychiatric follow-up. The interval is based on the prescribed product, not on how often symptoms are noticeable.

How Abilify Asimtufii works

Asimtufii releases aripiprazole over an extended period. Aripiprazole is thought to affect dopamine and serotonin signalling through partial receptor activation and receptor blocking. A larger number of milligrams on the syringe does not allow a direct comparison with the milligrams in a daily tablet or another injection.

Eligibility: Abilify Asimtufii

Oral aripiprazole tolerability must be known before starting. The prescriber reviews diagnosis, prior injections, interactions, side effects, pregnancy questions and the ability to keep scheduled care. People already receiving Maintena may have a labelled transition at the next scheduled Maintena injection. A transition from another medicine requires its own plan.

What to expect: Abilify Asimtufii

Review the current medicine record

Bring the exact dates and strengths of recent injections. Tell the clinician about changes in sleep, psychosis, mood, restlessness, weight or impulse control. These details help decide whether a longer interval suits the current treatment goal.

Agree on the starting regimen

For patients receiving an oral antipsychotic, the label allows a one-day regimen involving Asimtufii, a separate Maintena injection and one oral aripiprazole dose. A 14-day regimen instead uses Asimtufii with oral aripiprazole or the current oral antipsychotic. These are prescriber-directed alternatives.

Plan the two-month cycle

The usual interval is 56 days. The label permits specified timing flexibility around the scheduled dose. Confirm the next appointment before leaving, and arrange psychiatric review between injections when needed.

Preparing for your appointment

Bring the exact product name, prescribed strength, last injection date, oral medicine list and the responsible prescriber’s contact information. Include discharge notes, recent blood tests and any written start or restart plan. Tell the team about pregnancy, breastfeeding, allergies, seizures, fainting, substance use and new medicines or supplements. If a dose is delayed or records are unclear, contact the prescriber before travelling to an administration visit.

Risks and when to seek help

The boxed warning states that antipsychotics increase the risk of death in older adults with dementia-related psychosis. This medicine is not approved for that use. Discuss sedation, weight and metabolic changes, dizziness on standing, restlessness and involuntary movements. Report new compulsive gambling, shopping, eating or sexual urges. Avoid driving until you know how aripiprazole affects your alertness and coordination. A long interval means unwanted effects may take time to change after a dose adjustment. Seek emergency care for severe trouble breathing, throat or tongue swelling, loss of consciousness, or high fever with severe muscle stiffness and confusion. Contact the treating team promptly for new involuntary movements, severe restlessness, worsening psychosis, marked dizziness or troublesome injection-site symptoms. Do not wait for the next routine injection to report a serious concern.

Follow-up and treatment review

If more than 14 weeks have elapsed since the last injection, the label calls for restarting with a one-day or 14-day initiation regimen. Shorter gaps have a different approach. The prescriber should calculate the interval from the actual injection date. New symptoms or side effects need review even if the next injection is months away.

Appointments, costs and coverage

Before an injection appointment, ask which clinic can accept the prescription, how the medicine will be obtained, and which costs belong to the medicine, administration and psychiatry follow-up. A benefits check, prior authorization and medicine delivery are different steps. Ask for the proposed cost before each step. Manufacturer assistance has its own eligibility rules. Office-visit coverage does not establish medication coverage, and a listed clinic does not establish that the product is stocked or can be given there today.

Medical sources

• Abilify Maintena US prescribing information and patient labeling (DailyMed)
• NIMH: Schizophrenia
• NIMH: Mental Health Medications
• Abilify Asimtufii US prescribing information and patient labeling (DailyMed)